Preterm Infant Inhaled Albuterol Dosing

• Status: Completed
• Trial end date: 2014-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in premature babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung disease of prematurity and is associated with increased morbidity and mortality, longer hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication frequently used in premature infants with chronic lung disease and in people with asthma. It is believed to be safe, but the optimal dose for infants is not clear. The investigators hypothesize that albuterol may help a subset of premature infants with lung disease, but they need to determine the best dose prior to doing research about how effective it is for chronic lung disease/BPD. Response to each of three doses of albuterol will be measure using pulmonary function tests.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• very low birthweight infant (<1500g)

• gestational age at birth <32 weeks

• age 14 or more days and corrected to 28w0d to 33w6d gestational age

• continuing to require respiratory support and/or supplemental oxygen

Exclusion Criteria:

• chromosomal abnormalities

• major congenital anomalies

• congenital heart disease, except atrial septal defect and patent ductus arteriosus

• clinical providers determine subject too unstable to undergo pulmonary function testing